Jaguar Health Finalizes Highly Dilutive Financing Terms with $1.10 ELOC Floor and Forced Preferred Stock Redemption

summarizeSummary

Jaguar Health has finalized critical terms for its dilutive financing agreements, setting a low floor price for equity sales and introducing forced redemption clauses for preferred stock that could lead to significant shareholder dilution.

check_boxKey Events · Financing and Capital Events · JAGX

• ELOC Floor Price Set

  The Equity Line of Credit (ELOC) agreement now specifies a floor price of $1.10 per share for sales to C/M Capital, well below the current market price.

• Forced Preferred Stock Redemption

  The Series P Preferred Stock agreement includes a new "Consequences of Triggering Events" clause, allowing C/M Capital to force redemption of their preferred shares into common stock at a defined floor price if the company breaches covenants or after three years.

• ELOC Proceeds for Preferred Redemption

  10% of the net proceeds from the ELOC will be used to redeem outstanding shares of Series P Preferred Stock.

• Preferred Stock Proceeds Restricted

  Proceeds from the Preferred Stock Private Placement are designated for working capital and general corporate purposes, explicitly excluding debt satisfaction, security repurchase, or litigation settlement.

auto_awesomeAnalysis · JAGX · Life Sciences

This filing provides definitive details for the previously announced highly dilutive financing agreements with C/M Capital. The Equity Line of Credit (ELOC) now includes a specific floor price of $1.10 for share sales, significantly below the current market price, indicating potential for substantial dilution if the stock declines. Furthermore, the Series P Preferred Stock agreement introduces a "Forced Redemption" clause, allowing C/M Capital to convert their preferred shares into common stock at a low floor price if the company breaches covenants or after three years, posing a significant risk of further dilution for common shareholders.